|
DE19718012C1
(de)
*
|
1997-04-29 |
1998-10-08 |
Jenapharm Gmbh |
Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
|
|
US6559158B1
(en)
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
|
US6274591B1
(en)
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
JP2001526228A
(ja)
|
1997-12-22 |
2001-12-18 |
ユーロ−セルティーク，エス．エイ． |
オピオイド作動薬／拮抗薬の併用
|
|
CA2314896C
(en)
|
1997-12-22 |
2005-09-13 |
Euro-Celtique, S.A. |
A method of preventing abuse of opioid dosage forms
|
|
DE19853487A1
(de)
*
|
1998-11-19 |
2000-05-25 |
Fumapharm Ag Muri |
Verwendung von Dialkylfumaraten
|
|
US6451806B2
(en)
|
1999-09-29 |
2002-09-17 |
Adolor Corporation |
Methods and compositions involving opioids and antagonists thereof
|
|
US6469030B2
(en)
|
1999-11-29 |
2002-10-22 |
Adolor Corporation |
Methods for the treatment and prevention of ileus
|
|
HU229705B1
(en)
|
2000-02-08 |
2014-05-28 |
Euro Celtique Sa |
Tamper-resistant oral opioid agonist formulations
|
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
|
CN1525851A
(zh)
|
2001-05-11 |
2004-09-01 |
������ҩ������˾ |
抗滥用阿片样物质控释剂型
|
|
JP2005515960A
(ja)
*
|
2001-05-11 |
2005-06-02 |
エンドー ファーマシューティカルズ， インコーポレイティド |
乱用耐性のオピオイド投薬形態
|
|
US20030022909A1
(en)
*
|
2001-06-05 |
2003-01-30 |
University Of Chicago |
Use of methylnaltrexone to treat immune suppression
|
|
SI1416842T1
(sl)
|
2001-07-18 |
2009-06-30 |
Euro Celtique Sa |
Farmacevtske kombinacije oksikodona in naloksona
|
|
AU2002324624A1
(en)
|
2001-08-06 |
2003-02-24 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
|
ATE431738T1
(de)
|
2001-08-06 |
2009-06-15 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
|
ES2654819T3
(es)
*
|
2001-10-18 |
2018-02-15 |
Nektar Therapeutics |
Conjugados poliméricos de antagonistas de opioides
|
|
EP1492505B1
(en)
|
2002-04-05 |
2015-06-03 |
Euro-Celtique S.A. |
Pharmaceutical preparation containing oxycodone and naloxone
|
|
US7815934B2
(en)
|
2002-09-20 |
2010-10-19 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
MXPA05010819A
(es)
*
|
2003-04-08 |
2006-03-30 |
Progenics Pharm Inc |
Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
|
|
CA2811272C
(en)
*
|
2003-04-08 |
2016-12-20 |
Progenics Pharmaceuticals, Inc. |
Pharmaceutical formulations containing methylnaltrexone
|
|
EP1638607A1
(en)
*
|
2003-04-08 |
2006-03-29 |
Progenics Pharmaceuticals, Inc. |
Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
|
|
AU2013203378B2
(en)
*
|
2003-04-08 |
2016-09-15 |
Progenics Pharmaceuticals, Inc. |
Pharmaceutical formulations containing methylnaltrexone
|
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
|
US20060182692A1
(en)
*
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
|
WO2005058367A2
(en)
*
|
2003-12-16 |
2005-06-30 |
Nektar Therapeutics Al, Corporation |
Pegylated small molecules
|
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
EP1845989A1
(en)
*
|
2005-01-20 |
2007-10-24 |
Progenics Pharmaceuticals, Inc. |
Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
|
|
CA2594373A1
(en)
*
|
2005-01-28 |
2006-08-03 |
Euro-Celtique S.A. |
Alcohol resistant dosage forms
|
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
EP1695700A1
(en)
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
ES2714198T3
(es)
|
2005-03-07 |
2019-05-27 |
Univ Chicago |
Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
|
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
|
DE102006006532B4
(de)
*
|
2006-02-10 |
2007-11-08 |
Biogenerics Pharma Gmbh |
Pharmazeutische Zubereitung
|
|
SI2719378T1
(sl)
|
2006-06-19 |
2016-11-30 |
Alpharma Pharmaceuticals Llc |
Farmacevtski sestavki
|
|
TWI489984B
(zh)
|
2006-08-04 |
2015-07-01 |
Wyeth Corp |
用於非經腸道傳輸化合物之配方及其用途
|
|
US20080139654A1
(en)
*
|
2006-12-09 |
2008-06-12 |
Eric Mott Soderling |
Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
|
|
EP2565195B1
(en)
|
2007-03-29 |
2015-05-06 |
Wyeth LLC |
Peripheral opioid receptor and antagonists and uses thereof
|
|
JP2010522756A
(ja)
|
2007-03-29 |
2010-07-08 |
プロジェニックス ファーマシューティカルズ，インコーポレーテッド |
結晶形およびその使用
|
|
PL2137191T3
(pl)
|
2007-03-29 |
2016-12-30 |
|
Antagoniści obwodowego receptora opioidowego i ich zastosowania
|
|
US8748448B2
(en)
|
2007-10-18 |
2014-06-10 |
Aiko Biotechnology |
Combination analgesic employing opioid agonist and neutral antagonist
|
|
JP2011500686A
(ja)
*
|
2007-10-18 |
2011-01-06 |
アイコ バイオテクノロジー |
オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
AU2008349873B2
(en)
|
2008-02-06 |
2014-02-13 |
Progenics Pharmaceuticals, Inc. |
Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
|
|
CA2719134C
(en)
|
2008-03-21 |
2015-06-30 |
The University Of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
|
CA2729582C
(en)
|
2008-07-01 |
2017-09-19 |
University Of Chicago |
Particles containing an opioid receptor antagonist and methods of use
|
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
|
MY152279A
(en)
|
2009-03-10 |
2014-09-15 |
Euro Celtique Sa |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
|
US9056054B2
(en)
*
|
2009-06-25 |
2015-06-16 |
Elite Laboratories, Inc. |
Abuse resistant oral dosage forms
|
|
CN102918039B
(zh)
|
2010-03-11 |
2017-06-09 |
惠氏有限责任公司 |
甲基纳曲酮的口服制剂和亲脂盐
|
|
PH12012502083A1
(en)
|
2010-05-10 |
2017-07-26 |
Euro Celtique Sa |
Manufacturing of active-free granules and tablets comprising the same
|
|
EP2568965A1
(en)
|
2010-05-10 |
2013-03-20 |
Euro-Celtique S.A. |
Combination of active loaded granules with additional actives
|
|
US9700508B2
(en)
|
2010-05-10 |
2017-07-11 |
Euro-Celtique S.A. |
Pharmaceutical compositions comprising hydromorphone and naloxone
|
|
US10071089B2
(en)
|
2013-07-23 |
2018-09-11 |
Euro-Celtique S.A. |
Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
|
CA3042642A1
(en)
|
2013-08-12 |
2015-02-19 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
|
WO2015071380A1
(en)
|
2013-11-13 |
2015-05-21 |
Euro-Celtique S.A. |
Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
|
|
US9456986B2
(en)
|
2013-12-11 |
2016-10-04 |
Develco Pharma Schweiz Ag |
Naloxone mono preparation and multilayer tablet
|
|
US10105360B2
(en)
|
2013-12-11 |
2018-10-23 |
Develco Pharma Schweiz Ag |
Method and composition for the treatment of opioid induced constipation
|
|
US10172797B2
(en)
|
2013-12-17 |
2019-01-08 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
|
CA2955229C
(en)
|
2014-07-17 |
2020-03-10 |
Pharmaceutical Manufacturing Research Services, Inc. |
Immediate release abuse deterrent liquid fill dosage form
|
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
|
JP6686013B2
(ja)
|
2014-10-17 |
2020-04-22 |
サリックス ファーマスーティカルズ，インコーポレーテッド |
腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
|
|
AU2015336065A1
(en)
|
2014-10-20 |
2017-05-04 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended release abuse deterrent liquid fill dosage form
|
|
US20160256451A1
(en)
*
|
2015-03-06 |
2016-09-08 |
Develco Pharma Schweiz Ag |
Dosage of naloxone
|
|
US20160256452A1
(en)
*
|
2015-03-06 |
2016-09-08 |
Develco Pharma Schweiz Ag |
Composition Of Opioid Receptor Antagonists For Use In Treatment Of Constipation With Highly Increased Whole Gut Transit Time
|
|
WO2016193456A2
(en)
|
2015-06-03 |
2016-12-08 |
Develco Pharma Schweiz Ag |
Opioid receptor antagonist for use in treating patients with severe constipation
|
|
EP3290027A1
(en)
|
2016-09-02 |
2018-03-07 |
Develco Pharma Schweiz AG |
Method and composition for the treatment of opioid induced constipation
|
|
MX2021013488A
(es)
|
2019-05-07 |
2021-12-10 |
Bausch Health Ireland Ltd |
Formulaciones liquidas de dosis oral de metilnaltrexona.
|